Summary:
In patients with advanced diabetic nephropathy (CKD stages III-IV), Pentoxifylline (400 mg every 8 hours) significantly reduced microalbuminuria, preserved renal function, and improved cardiac morphology compared to placebo, though it was associated with no significant adverse events.
| PICO | Description |
|---|---|
| Population | Adults with chronic kidney disease stages III-IV due to diabetic nephropathy. |
| Intervention | Pentoxifylline 400 mg administered orally every 8 hours, over a 12-month period. |
| Comparison | Matching placebo treatment group over the same duration. |
| Outcome | At both 6 and 12 months, pentoxifylline significantly reduced microalbuminuria (up to -43.18 mg/24h at 12 months, p < 0.001), stabilized or improved eGFR (mean increase of 0.98 mL/min/1.73 m² at 12 months vs. decline in placebo, p = 0.008), and reduced left ventricular mass index (LVMI) (-0.82 g/m² vs. +20.79 g/m² in placebo, p = 0.028). No significant adverse events were observed. |
Source: Oliva Mejía-Rodríguez, et al. “Short- and Middle-Term Nephroprotective and Cardioprotective Effects of Pentoxifylline in Patients with Diabetic Nephropathy: A Randomized Controlled Trial.” Read article here.
